Want to see BAYRY full AI Analyst Report?
BAYRY Stock Chart & Stats
$14.30
$0.26(1.98%)
At close: 4:00 PM EDT
$14.30
$0.26(1.98%)
Day’s Range― - ―
52-Week Range$7.54 - $15.27
Previous CloseN/A
Volume684.76K
Average Volume (3M)43.90K
Market Cap
$50.43B
Enterprise Value$93.55B
Total Cash (Recent Filing)$4.29B
Total Debt (Recent Filing)$38.42B
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Nov 03, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend Yield0.25%
Share Statistics
EPS (TTM)-0.42
Shares Outstanding3,929,696,000
10 Day Avg. Volume0
30 Day Avg. Volume43,897
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.40
Price to Sales (P/S)0.83
P/FCF Ratio18.08
Enterprise Value/Market Cap1.86
Enterprise Value/Revenue2.06
Enterprise Value/Gross Profit3.48
Enterprise Value/Ebitda10.15
Forecast
1Y Price Target
$15.50Price Target Upside8.39% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)1.28
Revenue Forecast (FY)$52.19B
Bulls Say, Bears Say
Bulls Say
Pipeline And Portfolio ExpansionPriority regulatory review and new technology additions broaden Bayer’s future growth options across pharmaceuticals and agriculture. These initiatives can strengthen the portfolio over time by adding potential products and capabilities beyond existing franchises, although execution remains important.
Capital And Balance-sheet ActionsThe equity investment and successful bond placement provide significant financing capacity while supporting management’s expectation that net financial debt will decline. These actions can improve medium-term financial flexibility and help fund operations, litigation obligations, and strategic priorities.
Crop Science Growth And MarginCrop Science is showing both meaningful sales growth and strong profitability, indicating that higher-value seeds, traits, and licensing can support the segment beyond seasonal product demand. Sustained margin strength in a core division can provide an important earnings foundation.
Bears Say
Persistent Net LossesPersistent net losses show that strong gross margins are not yet translating into durable bottom-line profitability. Continued earnings weakness can restrict internally funded investment, reduce financial resilience, and make the business more dependent on operating improvement and capital-management actions.
Weakening Free Cash FlowThe sharp deterioration in free cash flow weakens cash conversion even though operating cash flow remains positive. If sustained, weaker discretionary cash generation could constrain debt reduction, investment, and shareholder distributions while increasing reliance on external financing.
Eylea Competitive PressureA 27% decline in Eylea sales highlights a structural competitive challenge in an important pharmaceutical franchise. Biosimilar pressure can continue to erode revenue and profit contribution, increasing the need for newer products such as Nubeqa and Kerendia to offset legacy-product deterioration.
Bayer News
BAYRY FAQ
What was Bayer’s price range in the past 12 months?
Bayer lowest stock price was $7.54 and its highest was $15.27 in the past 12 months.
What is Bayer’s market cap?
Bayer’s market cap is $50.43B.
When is Bayer’s upcoming earnings report date?
Bayer’s upcoming earnings report date is Nov 03, 2026 which is in 5 days.
How were Bayer’s earnings last quarter?
Bayer released its earnings results on Aug 04, 2026. The company reported $0.274 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.054.
Is Bayer overvalued?
According to Wall Street analysts Bayer’s price is currently Undervalued.
Does Bayer pay dividends?
Bayer pays a Annually dividend of $0.032 which represents an annual dividend yield of 0.25%. See more information on Bayer dividends here
What is Bayer’s EPS estimate?
Bayer’s EPS estimate is 0.11.
How many shares outstanding does Bayer have?
Bayer has 3,929,696,000 shares outstanding.
What happened to Bayer’s price movement after its last earnings report?
Bayer reported an EPS of $0.274 in its last earnings report, beating expectations of $0.22. Following the earnings report the stock price went up 2.477%.
Which hedge fund is a major shareholder of Bayer?
Currently, no hedge funds are holding shares in BAYRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bayer Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.50 (8.39% Upside)
$15.50 (8.39% Upside)
Blogger Sentiment
Bullish
BAYRY Sentiment 100%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
60.59%
12-Months-Change
Fundamentals
Return on Equity
-6.10%
Trailing 12-Months
Asset Growth
-0.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bayer
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
BAYRY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear operational and strategic positives — steady group sales (+3%), EBITDA improvement (+7%), Crop Science margin expansion to 31%, strong growth in several Pharma assets (Nubeqa and Kerendia +66%), successful capital transactions (EUR 3bn Apollo investment and USD 5bn bond issuance) and a favorable U.S. Supreme Court ruling that materially strengthens litigation containment. Offsetting these strengths are meaningful near-term financial drains: negative free cash flow (‑EUR 2.7bn) driven by EUR 2.5bn in litigation payouts, elevated net debt in the near term (EUR 33.6bn), a 17% drop in Q2 core EPS due to normalization, Eylea sales down 27%, and continued legal and external-market risks. On balance, the highlights materially outweigh the lowlights given improving profitability, strategic progress, and decisive financing actions that reduce medium-term balance-sheet risk.View all BAYRY earnings summariesBAYRY Stock 12 Month Forecast
Average Price Target
$15.50
▲(8.39% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.16% Mutual Funds
<0.01% Other Institutional Investors
99.83% Public Companies and
Individual Investors